Merck KGaA (MRK) Given a €105.00 Price Target by Societe Generale Analysts

Societe Generale set a €105.00 ($122.09) price objective on Merck KGaA (FRA:MRK) in a report published on Wednesday, March 27th, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

A number of other equities analysts have also weighed in on the stock. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a buy rating in a research report on Wednesday, December 12th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, January 8th. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, February 28th. Morgan Stanley set a €88.00 ($102.33) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, December 14th. Finally, Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have given a buy rating to the stock. Merck KGaA currently has a consensus rating of Hold and an average price target of €101.15 ($117.62).

Shares of MRK traded down €1.14 ($1.33) during mid-day trading on Wednesday, reaching €93.78 ($109.05). The stock had a trading volume of 684,754 shares. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: What is the Rule of 72?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.